New York is currently home to 4468 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
Recruiting
This study's long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: New York University School of Global Public Health, New York, New York
Conditions: Human Immunodeficiency Virus (HIV), Smoking Cessation
A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
06/04/2025
Locations: Intercity Gastroenterology, Fresh Meadows, New York
Conditions: Moderately to Severely Active Ulcerative Colitis
An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors
Recruiting
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 as monotherapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health, New York, New York
Conditions: Advanced Solid Tumor
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Recruiting
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: New York University (NYU) Langone Medical Center, New York, New York
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Recruiting
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
06/04/2025
Locations: UBMD Peds-Div of Endo/Diabetes, Buffalo, New York
Conditions: Obesity
A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study
Recruiting
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a f... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/04/2025
Locations: Teva Investigational Site 15549, New York, New York
Conditions: Multiple System Atrophy
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/04/2025
Locations: Suny Downstate Medical Center, Brooklyn, New York
Conditions: NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Montefiore Medical Center, East Syracuse, New York
Conditions: Prurigo Nodularis
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Recruiting
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in participants with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The study will begin with a safety lead-in phase (Phase 1b study) to determine the recommended combination dose (RDC) and then will transition to an expansion phase (Phase 2 study) to assess the clinical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Recruiting
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/04/2025
Locations: Research Site 2, Bronx, New York
Conditions: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Recruiting
The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. The study will begin as a Phase Ib study to determine the RCD and then will transition to a Phase II study to assess the clinical efficacy of vorasidenib at the RCD in combination with TMZ. During the treatment period participants will have study visits on day 1 and 22 of each cycle, with additional v... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/04/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: IDH1-mutant Glioma, IDH2-mutant Glioma